Clinical Trials

Leukemia, Myeloid, Acute

NCT05963074 2026-04-13

TAILOR

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06317649 2026-04-13

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

147 enrolled

Leukemia, Myeloid, Acute

NCT06504459 2026-04-13

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

40 enrolled

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT06672146 2026-04-13

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

93 enrolled

Leukemia, Myeloid, Acute

NCT06954987 2026-04-13

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

244 enrolled

Leukemia, Myeloid, Acute

NCT07153497 2026-04-13

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

MyeloidOther hematologic neoplasm

132 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07387471 2026-04-13

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

14 enrolled

Lymphoid

Waldenstrom Macroglobulinemia, Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT07437950 2026-04-13

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

126 enrolled

Leukemia, Myeloid, Acute

NCT03466294 2026-04-09

Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

Phase 2 Completed

42 enrolled 9 charts

Leukemia, Myeloid, Acute

NCT05442216 2026-04-08

TAGALONG

53 enrolled

Leukemia, Myeloid, Acute

NCT07514832 2026-04-07

VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial

48 enrolled

Leukemia, Myeloid, Acute

NCT07514936 2026-04-07

Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

120 enrolled

Phase 2 Active not recruiting

Leukemia, Myeloid, Acute

NCT03467867 2026-04-06

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

25 enrolled

Leukemia, Lymphoproliferative Disorders, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07507825 2026-04-02

VHAG

61 enrolled

Leukemia, Myeloid, Acute

NCT06660368 2026-04-01

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

52 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT03824483 2026-03-27

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

230 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05388006 2026-03-25

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05376111 2026-03-19

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

28 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06220162 2026-03-19

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

32 enrolled

Leukemia, Myeloid, Acute

NCT06561074 2026-03-16

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

22 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06510309 2026-03-13

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

33 enrolled

Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT06557421 2026-03-13

STOP VEN

50 enrolled

Leukemia, Myeloid, Acute

NCT07218510 2026-03-13

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

33 enrolled

Phase 2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04746235 2026-03-12

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

85 enrolled

Leukemia, Myeloid, Acute

NCT03226418 2026-03-10

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Phase 2 Completed

75 enrolled 14 charts